Safety, tolerability and pharmacokinetics of single rising oral doses and multiple oral doses of BI 1323495 versus placebo in healthy male Japanese subjects genotyped as poor and extensive metabolizers of UGT2B17 (single-blind, randomised, placebo-controlled [within dose groups] trial), including an investigation of drug-drug interaction with itraconazole in healthy male subjects genotyped as poor metabolizers of UGT2B17 (an open-label, two-period, fixed sequence trial)

Katakabe Tetsuya0 sites74 target enrollmentNovember 25, 2020

Overview

No summary available.

Registry

who.int

Start Date

November 25, 2020

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

Male

Sponsor

Katakabe Tetsuya

•1\. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history, including a medical examination, vital signs (BP, PR), 12\-lead ECG, and clinical laboratory tests
•2\. Japanese ethnicity, according to the following criteria:
•\- born in Japan, have lived outside of Japan \<10 years, and have parents and grandparents who are Japanese
•3\. Age of 20 to 45 years (inclusive) at screening
•4\. BMI of 18\.5 to 25\.0 kg/m2 (inclusive) at screening
•5\. Signed and dated written informed consent prior to admission to the trial, in accordance with Good Clinical Practice (GCP) and local legislation
•6\. Subjects who agree to minimize the risk of making their partner pregnant by fulfilling any of the following criteria starting from the first administration of trial medication until 90 days after last administration of trial medication
•\- Use of adequate contraception, any of the following methods plus condom: intrauterine device, combined oral contraceptives that started at least 2 months prior to the first drug administration.
•\- Vasectomized (vasectomy at least 1 year prior to enrolment)
•\- Surgical sterilization (including bilateral tubal occlusion, hysterectomy or bilateral oophorectomy) of the subject's female partner

•1\.Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
•2\.Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 40 to 90 mmHg, or pulse rate outside the range of 40 to 99 bpm
•3\.Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
•4\.Any evidence of a concomitant disease assessed as clinically relevant by the investigator
•5\.Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
•6\.Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
•7\.Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
•8\.History of relevant orthostatic hypotension, fainting spells, or blackouts
•9\.Chronic or relevant acute infections (Subjects who were positives to Hepatitis B surface antigen, Hepatitis B surface antibody, Hepatitis B core antibody, Hepatitis C antibodies, HIV\-1 and HIV\-2 antigen and/or antibody, T\-SPOT and Syphilis test)
•10\.History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)